Last reviewed · How we verify
Enteric Coated Aspirin
At a glance
| Generic name | Enteric Coated Aspirin |
|---|---|
| Also known as | Aspirin |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Aspirin to Target Arterial Events in Chronic Kidney Disease (PHASE3)
- Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty (PHASE2)
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (PHASE3)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial (EARLY_PHASE1)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT) (PHASE3)
- Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enteric Coated Aspirin CI brief — competitive landscape report
- Enteric Coated Aspirin updates RSS · CI watch RSS
- Dartmouth-Hitchcock Medical Center portfolio CI